Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AmEno
- Development stage
- Preclinical
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Oral
01
Overview
AmEno is a moonlighting protein, specifically enolase AmEno15, identified from the *Anaplasma marginale* strain MEX-15-099-01. It is being investigated for its potential as an immunogen in the design of vaccines against bovine Anaplasmosis. Synthetic peptides derived from AmEno have demonstrated antigenicity in ELISA assays, indicating its potential for stimulating an immune response. AmEno plays a significant role in the adhesion and invasion processes of *Anaplasma marginale* to host tissues, including erythrocytes and tick gut cells.
Beyond the preview
Go deeper on AmEno.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AmEno.